[1]
Ferrini, A.; Stevens, M.M.; Sattler, S.; Rosenthal, N. Toward regeneration of the heart: bioengineering strategies for immunomodulation. Front. Cardiovasc. Med., 2019, 6, 26.
[2]
Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; Kastelein, J.J.P.; Cornel, J.H.; Pais, P.; Pella, D.; Genest, J.; Cifkova, R.; Lorenzatti, A.; Forster, T.; Kobalava, Z.; Vida-Simiti, L.; Flather, M.; Shimokawa, H.; Ogawa, H.; Dellborg, M.; Rossi, P.R.F.; Troquay, R.P.T.; Libby, P.; Glynn, R.J. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med., 2017, 377(12), 1119-1131.
[3]
Tardif, J.C.; Kouz, S.; Waters, D.D.; Bertrand, O.F.; Diaz, R.; Maggioni, A.P.; Pinto, F.J.; Ibrahim, R.; Gamra, H.; Kiwan, G.S.; Berry, C.; López-Sendón, J.; Ostadal, P.; Koenig, W.; Angoulvant, D.; Grégoire, J.C.; Lavoie, M-A.; Dubé, M-P.; Rhainds, D.; Provencher, M.; Blondeau, L.; Orfanos, A.; L’Allier, P.L.; Guertin, M-C.; Roubille, F. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med., 2019, 381(26), 2497-2505.
[4]
Bengel, F.M.; Ross, T.L. Emerging imaging targets for infiltrative cardiomyopathy: Inflammation and fibrosis. J. Nucl. Cardiol., 2019, 26(1), 208-216.
[5]
Kempf, T.; Zarbock, A.; Vestweber, D.; Wollert, K.C. Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. J. Mol. Med., 2012, 90, 361-369.
[6]
Taqueti, V.R.; Mitchell, R.N.; Lichtman, A.H. Protecting the pump: controlling myocardial inflammatory responses. Annu. Rev. Physiol., 2006, 68, 67-95.
[7]
Lin, Y.; Zhu, W.; Chen, X. The involving progress of MSCs based therapy in atherosclerosis. Stem Cell Res. Ther., 2020, 11(1), 216.
[8]
Taqueti, V.R.; Jaffer, F.A. High-resolution molecular imaging via intravital microscopy: illuminating vascular biology in vivo. Integrative biology:
quantitative biosciences from nano to macro. 2013, 5, 278-290.
[9]
Taqueti, V.R.; Di Carli, M.F.; Jerosch-Herold, M.; Sukhova, G.K.; Murthy, V.L.; Folco, E.J.; Kwong, R.Y.; Ozaki, C.K.; Belkin, M.; Nahrendorf, M.; Weissleder, R.; Libby, P. Increased microvascularization and vessel permeability associate with active inflammation in human atheromata. Circ Cardiovasc Imaging, 2014, 7(6), 920-929.
[10]
Osborne, M.T.; Hulten, E.A.; Murthy, V.L.; Skali, H.; Taqueti, V.R.; Dorbala, S.; DiCarli, M.F.; Blankstein, R. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J. Nucl. Cardiol., 2017, 24(1), 86-99.
[11]
Genovesi, D.; Bauckneht, M.; Altini, C.; Popescu, C.E.; Ferro, P.; Monaco, L.; Borra, A.; Ferrari, C.; Caobelli, F. The role of positron emission tomography in the assessment of cardiac sarcoidosis. Br. J. Radiol., 2019, 92(1100)20190247
[12]
Chareonthaitawee, P.; Beanlands, R.S.; Chen, W.; Dorbala, S.; Miller, E.J.; Murthy, V.L.; Birnie, D.H.; Chen, E.S.; Cooper, L.T.; Tung, R.H.; White, E.S.; Borges-Neto, S.; Di Carli, M.F.; Gropler, R.J.; Ruddy, T.D.; Schindler, T.H.; Blankstein, R. Collab Group. Joint SNMMI-ASNC expert consensus document on the role of 18 F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J. Nucl. Med., 2017, 58(8), 1341-1353.
[13]
Taqueti, V.R.; Nahrendorf, M.; Di Carli, M.F. Translational molecular imaging: repurposing an old technique to track cell migration into human atheroma. J. Am. Coll. Cardiol., 2014, 64(10), 1030-1032.
[14]
Taqueti, V.R.; Grabie, N.; Colvin, R.; Pang, H.; Jarolim, P.; Luster, A.D.; Glimcher, L.H.; Lichtman, A.H. T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity. J. Immunol., 2006, 177(9), 5890-5901.
[15]
Jung, K.; Kim, P.; Leuschner, F.; Gorbatov, R.; Kim, J.K.; Ueno, T.; Nahrendorf, M.; Yun, S.H. Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts. Circ. Res., 2013, 112(6), 891-899.
[16]
Thackeray, J.T.; Bengel, F.M. Molecular imaging of myocardial inflammation with positron emission tomography post-ischemia: a determinant of subsequent remodeling or recovery. JACC Cardiovasc. Imaging, 2018, 11(9), 1340-1355.
[17]
Horckmans, M.; Ring, L.; Duchene, J.; Santovito, D.; Schloss, M.J.; Drechsler, M.; Weber, C.; Soehnlein, O.; Steffens, S. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur. Heart J., 2017, 38(3), 187-197.
[PMID: 28158426]
[PMID: 28158426]
[18]
Thackeray, J.T.; Bankstahl, J.P.; Wang, Y.; Wollert, K.C.; Bengel, F.M. Targeting amino acid metabolism for molecular imaging of inflammation early after myocardial infarction. Theranostics, 2016, 6(11), 1768-1779.
[19]
Thackeray, J.T.; Derlin, T.; Haghikia, A.; Napp, L.C.; Wang, Y.; Ross, T.L.; Schäfer, A.; Tillmanns, J.; Wester, H.J.; Wollert, K.C.; Bauersachs, J.; Bengel, F.M. Molecular imaging of the chemokine receptor CXCR4 after acute myocardial infarction. J. Am. Coll. Cardiol. Img, 2015, 8(12), 1417-1426.
[20]
Li, X.; Bauer, W.; Kreissl, M.C.; Weirather, J.; Bauer, E.; Israel, I.; Richter, D.; Riehl, G.; Buck, A.; Samnick, S. Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis, 2013, 230(1), 33-39.
[21]
Gaemperli, O.; Shalhoub, J.; Owen, D.R.; Lamare, F.; Johansson, S.; Fouladi, N.; Davies, A.H.; Rimoldi, O.E.; Camici, P.G. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur. Heart J., 2012, 33(15), 1902-1910.
[22]
Higuchi, T.; Bengel, F.M.; Seidl, S.; Watzlowik, P.; Kessler, H.; Hegenloh, R.; Reder, S.; Nekolla, S.G.; Wester, H.J.; Schwaiger, M. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc. Res., 2008, 78(2), 395-403.
[23]
Ramasamy, A.; Serruys, P.W.; Jones, D.A.; Johnson, T.W.; Torii, R.; Madden, S.P.; Amersey, R.; Krams, R.; Baumbach, A.; Mathur, A.; Bourantas, C.V. Reliable in vivo intravascular imaging plaque characterization: A challenge unmet. Am. Heart J., 2019, 218, 20-31.
[24]
Hyafil, F.; Schindler, A.; Sepp, D.; Obenhuber, T.; Bayer-Karpinska, A.; Boeckh-Behrens, T.; Höhn, S.; Hacker, M.; Nekolla, S.G.; Rominger, A.; Dichgans, M.; Schwaiger, M.; Saam, T.; Poppert, H. High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(2), 270-279.
[25]
Joshi, N.V.; Vesey, A.T.; Williams, M.C.; Shah, A.S.V.; Calvert, P.A.; Craighead, F.H.M.; Yeoh, S.E.; Wallace, W.; Salter, D.; Fletcher, A.M.; van Beek, E.J.R.; Flapan, A.D.; Uren, N.G.; Behan, M.W.H.; Cruden, N.L.; Mills, N.L.; Fox, K.A.; Rudd, J.H.; Dweck, M.R.; Newby, D.E. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet, 2014, 383(9918), 705-713.
[26]
Lairez, O.; Hyafil, F. A clinical role of pet in atherosclerosis and vulnerable plaques? Semin. Nucl. Med., 2020, 50(4), 311-318.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Cancer Genes
Cancer Medicine in an Ayurvedic Perspective: A Critical Overview
Cancer Genes
Anticancer Immunity: Reviewing the Potential of Probiotics
Probiotics in Anticancer Immunity
Phytonutrients in the Treatment of Gastrointestinal Cancer
Molecular Targets and Cancer Therapeutics (Part 2)
Molecular Targets and Cancer Therapeutics (Part 1)
Article Metrics
13